DAWSON'S encephalitis is a progressive degenerative disease of the central nervous system secondary to a chronic viral infection. Histologic, electron microscopic, immunologic, and immunofluorescent studies indicate that the etiologic agent in this disease is the rubeola virus. In addition, the rubeola virus has been cultured from brain tissue obtained at cerebral biopsy from several patients. As a chronic progressive infection of the brain, this disease might be susceptible to antiviral chemotherapy. Preliminary trials suggested that 5-bromo-2′-deoxyuridine (BUDR) might alter the course of the disease.1,2 To further evaluate this preliminary data, as well as to acquire detailed information regarding the course of Dawson's encephalitis, a double-blind study was undertaken using BUDR and placebo.
Materials and Methods
Patients were included in the study if all the following characteristics of Dawson's encephalitis were manifest2: (1) intellectual or personality change; (2) myoclonic jerks; (3) periodic bursts of slow wave or synchronous
Freeman JM. Treatment of Dawson's Encephalitis With 5-Bromo-2′-Deoxyuridine: Double-Blind Study. Arch Neurol. 1969;21(4):431–434. doi:10.1001/archneur.1969.00480160103012
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: